Affinity Asset Advisors LLC Acquires New Shares in Lexeo Therapeutics, Inc. $LXEO

Key Points

• Affinity Asset Advisors LLC has acquired 1,480,881 shares of Lexeo Therapeutics, valued at approximately $5.14 million, representing 4.46% ownership of the company.
• Recent analyst reports show a consensus rating of "Buy" for Lexeo Therapeutics, with an average price target of $15.33 after various firms adjusted their ratings and price targets.
• Lexeo Therapeutics reported a quarterly earnings per share (EPS) of ($0.60), which beat analyst expectations of ($0.64).

Affinity Asset Advisors LLC bought a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The firm bought 1,480,881 shares of the company's stock, valued at approximately $5,139,000. Affinity Asset Advisors LLC owned 4.46% of Lexeo Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Millennium Management LLC lifted its position in shares of Lexeo Therapeutics by 282.5% during the fourth quarter. Millennium Management LLC now owns 141,951 shares of the company's stock worth $934,000 after purchasing an additional 104,837 shares in the last quarter. Marshall Wace LLP purchased a new stake in Lexeo Therapeutics during the 4th quarter worth $117,000. BNP Paribas Financial Markets increased its stake in Lexeo Therapeutics by 523.1% during the 4th quarter. BNP Paribas Financial Markets now owns 34,527 shares of the company's stock worth $227,000 after buying an additional 28,986 shares during the period. Wellington Management Group LLP increased its stake in Lexeo Therapeutics by 48.3% during the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock worth $507,000 after buying an additional 25,089 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Lexeo Therapeutics by 30.1% during the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock worth $88,000 after buying an additional 3,093 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Oppenheimer assumed coverage on Lexeo Therapeutics in a report on Thursday, July 31st. They set an "outperform" rating and a $20.00 price objective on the stock. HC Wainwright dropped their price objective on Lexeo Therapeutics from $15.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Chardan Capital dropped their price objective on Lexeo Therapeutics from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, August 15th. Finally, JPMorgan Chase & Co. dropped their price objective on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 30th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $15.33.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock traded up $0.03 during mid-day trading on Friday, reaching $4.79. The company's stock had a trading volume of 232,724 shares, compared to its average volume of 305,068. The business has a 50 day moving average price of $4.45 and a 200-day moving average price of $3.67. Lexeo Therapeutics, Inc. has a twelve month low of $1.45 and a twelve month high of $11.96.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.04. Research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.